(19)

(11)

EP 4 398 889 A1

(12)

(43) Date of publication: 17.07.2024 Bulletin 2024/29 (21) Application number: 22786605.0 (22) Date of filing: 12.09.2022

(51) International Patent Classification (IPC):  A61K 31/00(2006.01) A61P 35/00(2006.01) C07K 16/28(2006.01) A61K 39/395(2006.01) C07K 16/18(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/555; A61K 31/7068; A61K 39/395; A61K 45/06; A61K 2039/505; A61K 2039/507; A61P 35/00; C07K 16/18; C07K 16/2818; C07K 2317/24; C07K 2317/76   C-Sets: A61K 39/395, A61K 2300/00; A61K 31/7068, A61K 2300/00; A61K 31/555, A61K 2300/00; (86) International application number: PCT/US2022/043226 (87) International publication number: WO 2023/039249 (16.03.2023 Gazette 2023/11)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 10.09.2021 US 202163242896 P 17.01.2022 US 202263300155 P 20.01.2022 US 202263301364 P 02.09.2022 US 202263403621 P (71) Applicants: Leap Therapeutics, Inc. Cambridge, MA 02141 (US) Beigene Switzerland GmbH 4051 Basel (CH)

(72) Inventors: KAGEY, Michael, H. Arlington, MA 02474 (US) SIRARD, Cynthia Cambridge, MA 02141 (US) BEN, Yong San Diego, CA 92130 (US) (74) Representative: Snodin, Michael D.  Park Grove IP MediCity Nottingham D6 Building, Thane Road Nottingham NG90 6BH Nottingham NG90 6BH (GB)